Biocon Gets US Regulator’s Nod For Biosimilar Of Cancer Drug, Shares Up 14%
New Delhi: Shares of Biocon...
Read MoreNew Delhi: Shares of Biocon...
Read MoreAs the fight against drug-resistant...
Read MoreA research team from Tongji...
Read MoreFibrocell Science, a gene therapy...
Read MoreAfter years of investigation, researchers...
Read MoreResearchers have recommended changes to...
Read MoreThere were two positive developments...
Read More